https://www.selleckchem.com/pr....oducts/fezolinetant.
An improvement in physical functioning of 7.3 ± 13.4 points (p = 0.002) with RAND/SF36 and in biomarker sIL-2R (-475.58 ± 1452.39; p = 0.005) was observed. Switching from originator infliximab Remicade® or biosimilar infliximab Inflectra® to biosimilar infliximab Flixabi® did not result in treatment discontinuation or loss of clinical/functional/inflammatory remission.(1) Background The heavy workload and understaffed personnel of village doctors is a challenge to the rural healthcare system in China. Previous studies have document
Like
Comment
Share
